Literature DB >> 2829024

Soluble CD4 molecules neutralize human immunodeficiency virus type 1.

A Traunecker1, W Lüke, K Karjalainen.   

Abstract

Human immunodeficiency virus (HIV) infection can bring about total collapse of the immune system by infecting helper T lymphocytes which express CD4, the molecule which mediates interaction between the cell surface and viral envelope glycoprotein gp120 (refs 3-10). HIV apparently escapes the effects of neutralizing antibodies in vivo by generating new variants which must still interact with CD4 to maintain a cycle of infection. One route to block HIV infection, therefore, could use solubilized CD4 protein to inhibit attachment of the virus to its target cell. We have used recombinant DNA techniques to generate soluble forms of CD4, and show here that these are potent inhibitors of HIV infection in vitro.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2829024     DOI: 10.1038/331084a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  112 in total

1.  Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells.

Authors:  D Schenten; L Marcon; G B Karlsson; C Parolin; T Kodama; N Gerard; J Sodroski
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Soluble receptor-induced retroviral infection of receptor-deficient cells.

Authors:  R Damico; P Bates
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

Review 3.  Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition.

Authors:  K J Connolly; S M Hammer
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

4.  Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants.

Authors:  P Kolchinsky; E Kiprilov; J Sodroski
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4.

Authors:  R A Byrn; I Sekigawa; S M Chamow; J S Johnson; T J Gregory; D J Capon; J E Groopman
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

6.  Analytic results for quantifying HIV infectivity.

Authors:  J L Spouge; S P Layne; M Dembo
Journal:  Bull Math Biol       Date:  1989       Impact factor: 1.758

7.  Aminosugar derivatives as potential anti-human immunodeficiency virus agents.

Authors:  A Karpas; G W Fleet; R A Dwek; S Petursson; S K Namgoong; N G Ramsden; G S Jacob; T W Rademacher
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

8.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

Review 9.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

10.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.